Soluble MICB in malignant diseases: Analysis of diagnostic significance and correlation with soluble MICA

Cancer Immunology, Immunotherapy

Volumn 55, Issue 12, 2006, Pages 1584-1589

  Holdenrieder, Stefan ^a   Stieber, Petra ^a   Peterfi, Andrea ^b   Nagel, Dorothea ^a   Steinle, Alexander ^c   Salih, Helmut Rainer ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cancer; Diagnosis; MICA; MICB; NKG2D; Serum

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN MICA; PROTEIN MICB; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; CANCER STAGING; CD8+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LIGANDS; NEOPLASM STAGING; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, IMMUNOLOGIC; RECEPTORS, NATURAL KILLER CELL; SOLUBILITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33748323243     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0167-1     Document Type: Article

References (28)

1. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-729
2. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T (2001) Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2:255-260
3. Gasser S, Orsulic S, Brown EJ, Raulet DH (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436:1186-1190
4. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T (1999) Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96:6879-6884
5. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102:1389-1396
6. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-171
7. Cerwenka A, Baron JL, Lanier LL (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98:11521-11526
8. Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225-274
9. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62:6178-6186
10. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100:4120-4125
11. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M (2004) RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 64:7596-7603
12. Kriegeskorte AK, Gebhardt FE, Porcellini S, Schiemann M, Stemberger C, Franz TJ, Huster KM, Carayannopoulos LN, Yokoyama WM, Colonna M, Siccardi AG, Bauer S, Busch DH (2005) NKG2D-independent suppression of T cell proliferation by H60 and MICA. Proc Natl Acad Sci USA 102:11805-11810
13. Salih HR, Rammensee HG, Steinle A (2002) Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169:4098-4102
14. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738
15. Yokoyama WM (2002) Immunology: catch us if you can. Nature 419:679-680
16. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle AL, Salih HR (2006) Soluble MICA in malignant diseases. Int J Cancer 118:684-687
17. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B, Vyas YM (2003) Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 171:6891-6899
18. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR (2004) Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114:560-568
19. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S, Pistoia V (2004) Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 6:558-568
20. Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, Eknigk U, Rammensee HG, Steinle A (2003) Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol 33:194-203
21. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T (1996) Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 93:12445-12450
22. Schalhorn A, Fuerst H, Stieber P (2001) Tumor markers in lung cancer. J Lab Med 25:353-361
23. Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H, Meier W, Fateh-Moghadam A (1993) CYFRA 21-1. A new marker in lung cancer. Cancer 72:707-713
24. Stieber P, Molina R, Chan DW, Fritsche HA, Beyrau R, Bonfrer JM, Filella X, Gornet TG, Hoff T, Jager W, van Kamp GJ, Nagel D, Peisker K, Sokoll LJ, Troalen F, Untch M, Domke I (2003) Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients. Clin Lab 49:15-24
25. Molina R, Filella X, Auge JM (2004) ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 37:505-511
26. Stieber P, Yamaguchi K (2002) ProGRP enables diagnosis of small-cell lung cancer. In: Diamandis EP, Frische HA, Lilja H, Chan DW, Schwartz MK (eds) Tumor markers; physiology, pathobiology, technology, and clinical applications, 1st edn. AACC, Washington, pp. 517-521
27. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Vinolas N, Marquez A, Barreiro E, Borras J, Viladiu P (2003) Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 24:209-218
28. Onda H, Ohkubo S, Shintani Y, Ogi K, Kikuchi K, Tanaka H, Yamamoto K, Tsuji I, Ishibashi Y, Yamada T, Kitada C, Suzuki N, Sawada H, Nishimura O, Fujino M (2001) A novel secreted tumor antigen with a glycosylphosphatidylinositol-anchored structure ubiquitously expressed in human cancers. Biochem Biophys Res Commun 285:235-243